TukysaActive Ingredient(s): Tucatinib
FDA Approved: * April 17, 2020
Pharm Company: * SEATTLE GENETICS
Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics). Common side effects are diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.